Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-04-01 07:00:00
Management to host webcast on April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET
Oslo, Norway, April 1, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, hosts a webcast presentation
of the 2021 financial results conducted by CEO Michael Engsig and other members
of management April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET.
The slide presentation is attached to this announcement and is also available in
the Investors section of the Company's website at www.nykode.com/investors. The
live and archived webcast of the presentation can be accessed in the Investors
section of the Company's website
www.nykode.com/investors/financial-reports-and-presentations.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer